Short answer
Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). Press release covers Lexeo’s business highlights and financial results for the three and nine months ended September 30, 2026.
Lexeo Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Lexeo’s business highlights and financial results for the three and nine months ended September 30, 2026
- Investors should review Exhibit 99.1 for earnings figures, cash position, pipeline updates and forward operating implications
Item 7.01 · Regulation FD Disclosure
- Corporate presentation attached as Exhibit 99.2 for the referenced webcast
- Investor relevance depends on pipeline, clinical, regulatory, or financing updates in the presentation
Item 8.01 · Other Events
- Positive interim Phase I/II data announced for LX2020 targeting PKP2-associated arrhythmogenic cardiomyopathy
- Regulatory updates for LX2020 create potential development-pathway implications
- Investor conference call and webcast scheduled for November 16, 2026 at 8:00 a.m. ET
- Updated corporate presentation posted, supporting ongoing investor and analyst outreach
Item EX-99.1 · Exhibit EX-99.1
- High-dose LX2020 cohorts showed 80% mean NSVT reduction and 44% mean PVC reduction at latest assessment, supporting clinical proof-of-concept
- FDA openness to NSVT as a primary surrogate endpoint strengthens potential accelerated-approval pathway, with pivotal design expected in 1H 2027
- Safety generally favorable across 10 participants, though liver-test elevations and one Grade 3 ventricular tachycardia event remain monitoring considerations
- Cash, cash equivalents and investments of $219.1 million expected to fund operations into 2028, reducing near-term financing pressure
- Q3 net loss widened to $38.3 million from $20.3 million, while R&D expense rose to $34.5 million from $15.7 million due partly to acquisition and milestone costs
Item EX-99.2 · Exhibit EX-99.2
- Phase 1/2 HEROIC-PKP2 interim data: high-dose LX2020 reduced mean NSVT 80% and PVC burden 44% at latest assessment, n=7
- Five of seven high-dose participants reported symptom improvement, while cardiac MRI showed stabilization or improvement in most participants
- Safety profile generally favorable across 10 participants, with no clinically significant complement activation or study discontinuations
- FDA open to guideline-defined NSVT as a potential accelerated-approval surrogate endpoint
- Pivotal-study design expected in 1H 2027, with initiation targeted for 2H 2027
Item EX-99.3 · Exhibit EX-99.3
- Corporate overview highlights LX2006 as Lexeo’s lead FA-cardiomyopathy asset, with potential first disease-modifying gene therapy in a high-unmet-need market
- SUNRISE-FA 2 pivotal study initiated June 2026, enrolling 26 participants with 13 treated at 1.2×10¹² vg/kg
- Topline SUNRISE-FA 2 data expected 2H 2027, with potential accelerated-approval BLA submission targeted for 1H 2028
- Phase I/II data showed approximately 18% LVMi reduction at 6 months, rising to approximately 28% in higher-dose cohorts
- Lexeo projects cash runway into 2028, supporting execution through pivotal data and potential regulatory filing catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lexeo Therapeutics, Inc. 8-K filings
Get the next LXEO 8-K as it lands
Follow LXEO for push alerts, or ask the research agent what this filing means.